Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  GlaxoSmithKline Pharmaceuticals Limited    GLAXO   INE159A01016

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote National Stock Exchange O…
01/16/2017 01/17/2017 01/18/2017 01/19/2017 01/20/2017 Date
2733.3(c) 2713(c) 2743.9(c) 2750.05(c) 2752.7 Last
4 151 4 769 5 209 5 506 5 016 Volume
+0.82% -0.74% +1.14% +0.22% +0.10% Change
More quotes
Financials ( INR)
Sales 2017 30 708 M
EBIT 2017 5 133 M
Net income 2017 4 191 M
Finance 2017 8 029 M
Yield 2017 1,97%
Sales 2018 34 874 M
EBIT 2018 6 940 M
Net income 2018 5 484 M
Finance 2018 4 453 M
Yield 2018 2,10%
P/E ratio 2017 55,76
P/E ratio 2018 42,61
EV / Sales2017 7,34x
EV / Sales2018 6,57x
Capitalization 233 514 M
More Financials
Company
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals.The company's product portfolio includes prescription medicines and vaccines.Its prescription medicines range across therapeutic areas such as anti-infective, dermatology,... 
Sector
Pharmaceuticals
Calendar
02/11Earnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline Pharmaceut
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE PHARMACEUT
01/19 TOP NEWS : GlaxoSmithKline Poaches AstraZeneca's Miels To Lead Pharma
01/17 GLAXOSMITHKLINE PHARMACEUTICALS : AKD Securities Limited Equity Research - Trigg..
01/16 GLAXOSMITHKLINE PHARMACEUTICALS : Taurus Securities Limited Market Roundup
01/16 GLAXOSMITHKLINE PHARMACEUTICALS : Recovery ahead
01/06 IT and Pharma sectors on shaky ground in early 2017
01/03 ENGRO : AKD Securities Limited Equity Research - Trigger Shark
01/03 ENGRO : AKD Securities Limited Equity Research - Trigger Shark
2016 GLAXOSMITHKLINE PLC (NYSE : GSK) Phase 3 Trials Looks Positive: Will Gilead Endu..
2016 UPDATE : Glaxo's ViiV Gets Positive HIV Study Results, Begins New Trial
2016 TOP NEWS : Glaxo's ViiV Gets Positive Results On Two-Drug HIV Treatment
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
Latest Tweets
01/14Biggest advantage for homebuyers will be lower interest rates, transparency &..
32
01/14Demonetisation will ensure smaller home developers will get formalised: Deepa..
17
01/14There is a deep conviction that India will emerge much stronger force after d..
62
01/14Hoping that many developers now will move towards affordable homes: Deepak Pa..
7
01/14DEEPAK PAREKH : Hoping that many developers now will move towards affordable ..
1
More tweets
Qtime:32
Advertisement
Chart GLAXOSMITHKLINE PHARMACEUT
Duration : Period :
GlaxoSmithKline Pharmaceut Technical Analysis Chart | GLAXO | INE159A01016 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE P...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 2 900  INR
Spread / Average Target 5,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Deepak Shantilal Parekh Non-Executive Chairman
Andrew Aristidou Chief Financial Officer & Executive Director
Raju Krishnaswamy Executive Director & Technical Director
Vrishali Desai Vice President-Medical & Clinical Research
D. Sundaram Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PHARMA..0.83%3 431
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results